Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00054795 | Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) | PHASE3 | COMPLETED | 550 | — | — | - | - | May 8, 2007 | 92 | United States, Australia +6 |
| Name | Type | Description |
|---|---|---|
| Motexafin Gadolinium | DRUG | - |
Inclusion Criteria: * Adults (≥18 years old) with radiologically proven parenchymal brain metastases from histologically confirmed non-small cell lung cancer; * KPS score of ≥70; * Each patient must sign a study-specific Informed Consent form Exclusion Criteria: * Liver metastases; * Extracranial...